Report cover image

Brain Tumor Therapeutics Market by Type (Glioblastoma, Meningioma, Metastatic Brain Tumors), Therapy (Chemotherapy, Gene Therapy, Immunotherapy), Patient Age Group, Distribution Channel, End-User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 199 Pages
SKU # IRE18436460

Description

Brain Tumor Therapeutics Market by Type (Glioblastoma, Meningioma, Metastatic Brain Tumors), Therapy (Chemotherapy, Gene Therapy, Immunotherapy), Patient Age Group, Distribution Channel, End-User - Global Forecast 2024-2030


The Brain Tumor Therapeutics Market size was estimated at USD 3.03 billion in 2023 and expected to reach USD 3.28 billion in 2024, at a CAGR 8.24% to reach USD 5.28 billion by 2030.

Global Brain Tumor Therapeutics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Brain Tumor Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Brain Tumor Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Brain Tumor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adcendo ApS, AIVITA Biomedical, Inc., Amgen Inc., AstraZeneca PLC, Aura Biosciences, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, CNS Pharmaceuticals, Inc., Curtana Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Eisai Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc., Gentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc., Merck & Co. Inc., Merck KGaA, Novartis AG, Novocure GmbH, Pfizer Inc., Qiagen N.V., Sanofi S.A., Siemens Healthcare GmbH, and Y-mAbs Therapeutics, Inc..

Market Segmentation & Coverage



This research report categorizes the Brain Tumor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Glioblastoma
Meningioma
Metastatic Brain Tumors
Pituitary Tumors
Therapy
Chemotherapy
Gene Therapy
Immunotherapy
Radiation Therapy
Targeted Therapy
Tissue Engineering
Patient Age Group
Adult
Pediatric
Distribution Channel
Offline Pharmacies
Online Pharmacies
End-User
Ambulatory Surgical Centers
Hospitals
Specialty Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Brain Tumor Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Brain Tumor Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Brain Tumor Therapeutics Market?
4. What is the market share of the leading vendors in the Brain Tumor Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Brain Tumor Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

199 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Brain Tumor Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of brain cancer and other neurological disorders
5.1.1.2. Rising need for tests detecting the presence of tumors
5.1.1.3. Research activities in the molecular diagnostics
5.1.2. Restraints
5.1.2.1. High cost associated with the diagnosis and treatment
5.1.3. Opportunities
5.1.3.1. Rising healthcare expenditure and the favorable reimbursement policies
5.1.3.2. Government initiatives for cancer awareness
5.1.4. Challenges
5.1.4.1. Side effects associated with brain tumor therapeutics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Brain Tumor Therapeutics Market, by Type
6.1. Introduction
6.2. Glioblastoma
6.3. Meningioma
6.4. Metastatic Brain Tumors
6.5. Pituitary Tumors
7. Brain Tumor Therapeutics Market, by Therapy
7.1. Introduction
7.2. Chemotherapy
7.3. Gene Therapy
7.4. Immunotherapy
7.5. Radiation Therapy
7.6. Targeted Therapy
7.7. Tissue Engineering
8. Brain Tumor Therapeutics Market, by Patient Age Group
8.1. Introduction
8.2. Adult
8.3. Pediatric
9. Brain Tumor Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Offline Pharmacies
9.3. Online Pharmacies
10. Brain Tumor Therapeutics Market, by End-User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Brain Tumor Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Brain Tumor Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Brain Tumor Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. Adcendo ApS
15.1.3. AIVITA Biomedical, Inc.
15.1.4. Amgen Inc.
15.1.5. AstraZeneca PLC
15.1.6. Aura Biosciences, Inc.
15.1.7. Bayer AG
15.1.8. Becton, Dickinson and Company
15.1.9. Bio-Rad Laboratories, Inc.
15.1.10. Bristol-Myers Squibb Company
15.1.11. CNS Pharmaceuticals, Inc.
15.1.12. Curtana Pharmaceuticals
15.1.13. Dr. Reddy’s Laboratories Ltd.
15.1.14. Eisai Inc.
15.1.15. Eli Lilly and Company
15.1.16. F. Hoffmann-La Roche AG
15.1.17. GE HealthCare Technologies Inc.
15.1.18. Gentech, Inc.
15.1.19. GlaxoSmithKline PLC
15.1.20. Illumina, Inc.
15.1.21. Johnson & Johnson Services, Inc.
15.1.22. Merck & Co. Inc.
15.1.23. Merck KGaA
15.1.24. Novartis AG
15.1.25. Novocure GmbH
15.1.26. Pfizer Inc.
15.1.27. Qiagen N.V.
15.1.28. Sanofi S.A.
15.1.29. Siemens Healthcare GmbH
15.1.30. Y-mAbs Therapeutics, Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. BRAIN TUMOR THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BRAIN TUMOR THERAPEUTICS MARKET DYNAMICS
FIGURE 7. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
FIGURE 10. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
FIGURE 12. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us